For much of the past year, the UK’s medicines pricing debate has cast a long shadow over the life sciences sector. The deadlock over NHS rebates – and the uncertainty surrounding the successor to VPAG ...

DEA reclassification of marijuana to Schedule III could boost cannabis industry growth. Federal illegality and regulatory issues pose investment risks in the cannabis sector. Understanding market ...